Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...
A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia ...
Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...
The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the ...
Penelope Oliver, a volunteer with Students Demand Action in California, talks to Hal about state laws involving firearms.
Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...
This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...
Among GLP-1 patients, prescription drug costs drove most of the spending increase. (Image Credits: Pixabay) An analysis of U.S. health insurance claims has revealed that drugs like Wegovy may trim ...
Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...
A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain high-risk breast cancer settings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback